SEC Form 4 · accession 0001209191-19-007490
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neal Walker
Officer — President and CEO · Director
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 6:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 1, 2019 | M | 10,800 | — | A | 920,924 | D | |
| Common Stock | Feb 1, 2019 | F | 3,579 | $6.96 | D | 917,345 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Feb 1, 2019 | M | 10,800 | D | — | — | Common Stock | 10,800 | 32,400 | D |
Explanation of responses
- F1Restricted stock units convert into common stock on a one-for-one basis.
- F2The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4.
- F3The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.